pharmaphorum

AUGUST 26, 2022

Among the claims is that Comirnaty was developed using a chemical modification to prevent causing an unwanted immune response in patients which was discovered by Moderna scientists, and that the use of a lipid nanoparticle formulation also infringes its intellectual property.

Vaccine 59

Vaccine Vaccination Sales Immune Response 59

pharmaphorum

MAY 31, 2022

In February, the company reacquired full rights to the shot from Astellas, which paid $10 million upfront to license the vaccine in 2017, clearing the way for GSK’s acquisition. billion in sales last year. billion in sales last year.

Vaccine 52

Vaccine Vaccination Bacterium Sales 52

pharmaphorum

DECEMBER 21, 2020

Each programme includes undisclosed upfront and milestone payments plus royalties on sales, with Merck indicating in a statement that it will be funding the research. Just a few weeks ago, Merck (known as MSD outside North America) paid $425 million to get hold of OncoImmune.

Immune Response 59

Immune Response Sales Antibody Drugs 59

The Pharma Data

JANUARY 12, 2021

Biond Biologics announced today that it has entered into a potentially $1 billion global licensing agreement with Sanofi to take a joint stab at defeating advanced forms of cancer with a more comprehensive and expedited approach to immuno-oncology. . Keitma/Shutterstock.

Immune Response 52

Immune Response Clinical Trials Clinical Trials Development 52

pharmaphorum

JUNE 22, 2022

Merck also sells an older shot called Pneumovax 23, which covers 23 serotypes but is based on an older polysaccharide technology that does not stimulate the immune response as strongly as the newer conjugate vaccines. Sales dipped to $5.2 billion.

Vaccine 52

Vaccine Vaccination Immune Response Sales 52

XTalks

MAY 1, 2023

Tofersen was discovered by Ionis Pharmaceuticals, and Biogen licensed tofersen from Ionis under a collaborative development and license agreement. At its peak sales, Qalsody is expected to generate around $300 million for Biogen. The recommended dosage of Qalsody is 100 mg (15 mL) per administration. What is SOD1 -ALS?

FDA Approval 89

FDA Approval Gene Genetics Protein 89

pharmaphorum

JANUARY 4, 2023

They both also include tiered royalties on sales of any products emerging from the partnerships. The hypothesis is that it will induce immune tolerance by stimulating anti-inflammatory regulatory T- (Treg) cells and cytokines that dampen down the immune response.

Immune Response 52

Immune Response Engineer Licensing Licensing 52

The Pharma Data

FEBRUARY 8, 2021

Q4 2020 sales growth (2) of 4.2% Specialty Care sales grew 18.3%, driven by strong Dupixent ® performance (+54.2% Diabetes sales, COVID environment and portfolio streamlining. Diabetes sales, COVID environment and portfolio streamlining. Sales down 2.4% Sales down 2.4% Sales increased 3.3%

Sales 52

Sales Vaccine Vaccination Production 52

The Pharma Data

FEBRUARY 4, 2021

Q4 2020 sales growth (2) of 4.2% Specialty Care sales grew 18.3%, driven by strong Dupixent ® performance (+54.2% Diabetes sales, COVID environment and portfolio streamlining. Diabetes sales, COVID environment and portfolio streamlining. Sales down 2.4% Sales down 2.4% Sales increased 3.3%

Sales 52

Sales Vaccine Vaccination Production 52

The Pharma Data

APRIL 27, 2021

Q1 2021 sales increase of 2.4% Specialty Care sales grew 15.3%, due to strong Dupixent ® performance (+45.6% General Medicines core assets grew 4.4%, while GBU sales were down 3.8%. Q1 2021 business EPS ( 1) growth at CER driven by efficiency and sales performance, supported by a one-time payment. IFRS net sales reported.

Sales 52

Sales Vaccine Vaccination Medicine 52

XTalks

MAY 2, 2024

The Prescription Drug User Fee Act (PDUFA) date is the deadline that the FDA sets for reviewing a New Drug Application (NDA) or Biologics License Application (BLA) and making a final decision on marketing approval. The firm predicts sales of KarXT could reach $2.8 billion ($1.5 billion) for the year.

Drugs 52

Drugs FDA Approval Vaccination Vaccine 52

pharmaphorum

JUNE 2, 2021

The 50 mcg dose was put through its paces in a study reported last month which found that it was able to generate an encouraging immune response against some key SARS-CoV-2 variants, including the Brazil and South Africa strain – when administered as a booter to previously vaccinated individuals.

Vaccine 52

Vaccine Vaccination Contract Manufacturing Production 52

The Pharma Data

DECEMBER 23, 2020

All 38 subjects who were evaluable for immunogenicity had balanced cellular and humoral immune responses following the second dose of INO-4800. The antigen is processed naturally in the cell and triggers the desired T cell and antibody-mediated immune responses. About INOVIO.

DNA 40

DNA Vaccine Vaccination Immune Response 40

The Pharma Data

JANUARY 31, 2021

Delivery of viral antigens in potent vaccine vectors to elicit a strong immune response is a cornerstone of successful infectious disease vaccines,” said Karin Jooss, PhD, Executive Vice President of Research and Chief Scientific Officer of Gritstone. This press release features multimedia.

Vaccine 52

Vaccine Vaccination Clinical Trials Clinical Trials 52

The Pharma Data

NOVEMBER 9, 2020

Amgen will record sales in the U.S. and AstraZeneca will record sales in Canada. Amgen will record sales as collaboration revenue. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. Outside the U.S.,

Trials 52

Trials Production Sales Manufacturing 52

The Pharma Data

DECEMBER 15, 2020

These proinflammatory T cells promoted bacterial clearance after infection with Staphylococcus aureus and, by licensing encephalitogenic Th17 cells, played a key role in the development of autoimmune disease in the central nervous system,” the authors stated. Anti-CD40L Antibody.

Clinical Trials 52

Clinical Trials Clinical Trials Antibody Trials 52

The Pharma Data

AUGUST 22, 2021

More than 75% of participants had co-morbidities, which include conditions that have been reported to cause a reduced immune response to vaccination. Under the terms of the licensing agreement with Vanderbilt, AstraZeneca will pay single-digit royalties on future net sales. About AstraZeneca.

Trials 52

Trials Antibody Vaccination Vaccine 52

The Pharma Data

AUGUST 3, 2021

The company announced donanemab received Breakthrough Therapy designation for treatment of Alzheimer’s disease and its intention to submit a biologics license application (BLA) for donanemab under the accelerated approval pathway later this year based on data from TRAILBLAZER-ALZ. million of revenue from sales of COVID-19 antibodies.

Antibody 52

Antibody Sales Development Production 52

The Pharma Data

JULY 8, 2021

Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) and granted Priority Review for tezepelumab in the treatment of asthma. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles.(24,25) Outside the U.S.,

Allergies 52

Allergies Trials In-Vivo Medicine 52

The Pharma Data

DECEMBER 21, 2020

Amgen will record sales in the U.S. and AstraZeneca will record sales in Canada. Amgen will record sales as collaboration revenue. TSLP is released in response to multiple triggers associated with asthma exacerbations, including allergens, viruses and other airborne particles. Outside the U.S.,

Trials 40

Trials Production Sales Manufacturing 40

The Pharma Data

DECEMBER 29, 2020

The analysis was prospectively designed to focus on patients who had not yet mounted their own immune response to SARS-CoV-2 (i.e., The EUA is temporary and does not take the place of a formal biologics license application (BLA) submission review and approval process and the use of the antibody cocktail remains investigational.

Antibody 52

Antibody Trials Production Clinical Trials 52

The Pharma Data

NOVEMBER 20, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as casirivimab and imdevimab have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

Antibody 52

Antibody Production Clinical Trials Clinical Trials 52

The Pharma Data

SEPTEMBER 15, 2020

On a non-risk adjusted basis, these opportunities collectively represent more than $15 billion (excluding 20vPnC) in potential incremental revenue for Pfizer from 2020 to 2025, as well as aggregate peak annual sales potential of $35 billion to $40 billion (including 20vPnC).

Vaccine 52

Vaccine Vaccination Gene Therapy Trials 52

The Pharma Data

OCTOBER 28, 2020

“We continue to see the strongest effects in patients who are most at risk for poor outcomes due to high viral load, ineffective antibody immune response at baseline, or pre-existing risk factors. Yancopoulos , M.D., President and Chief Scientific Officer of Regeneron. Regeneron has shared these results with the U.S.

Antibody 40

Antibody Trials Production Clinical Trials 40

The Pharma Data

NOVEMBER 21, 2020

The clinical evidence from Regeneron’s outpatient trial suggests that monoclonal antibodies such as REGEN-COV2 have the greatest benefit when given early after diagnosis and in patients who have not yet mounted their own immune response or who have high viral load.

Antibody 40

Antibody Production Clinical Trials Clinical Trials 40

The Pharma Data

OCTOBER 28, 2020

Mesoblast has formally requested a Type A meeting with the FDA to discuss a potential accelerated approval of the Biologics License Application (BLA) for remestemcel-L for the treatment of SR-aGVHD in children, with an additional randomized controlled study in patients 12 years and older as a post-approval requirement.

Production 40

Production Trials Manufacturing Development 40

The Pharma Data

DECEMBER 17, 2020

Senior Vice President and Head of Global Clinical Development at Regeneron and lead author of the publication. “The investigational cocktail is now available to indicated high-risk U.S. patients under an Emergency Use Authorization, and we also continue a robust clinical development program.”

Antibody 52

Antibody Medicine Production Trials 52